PT - JOURNAL ARTICLE AU - Borges, Julian Yin Vieira TI - The Role of Coenzyme Q10 in Cardiovascular Disease Treatment: An Updated 2024 Systematic Review and Meta-Analysis of Prospective Cohort Studies (1990-2024) AID - 10.1101/2024.07.03.24309736 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.03.24309736 4099 - http://medrxiv.org/content/early/2024/07/16/2024.07.03.24309736.short 4100 - http://medrxiv.org/content/early/2024/07/16/2024.07.03.24309736.full AB - Background and Objectives With the increasing need for clinicians to develop novel treatment strategies for the treatment of CVDs, the future lies in developing personalized nutrient recommendations based on an individual’s needs. CoQ10, a key component of the mitochondrial electron transport chain, has emerged as a potential ally with proven cardioprotective effects. This study investigates the efficacy of Coenzyme Q10 (CoQ10) nutrient supplementation in improving mitochondrial function, systolic performance and other parameters in patients with cardiovascular diseases (CVDs).Methods A systematic review and meta-analysis included data from PubMed, Embase, and the Cochrane Library up to January 2024. Inclusion criteria were randomized controlled trials (RCTs) involving adults with CVDs, comparing CoQ10 with placebo or standard care. Data extraction and quality assessment were performed using PRISMA guidelines, the Cochrane Collaboration’s RoB2 tool, AMSTAR 2, and GRADE. Primary outcome: mitochondrial function (ATP production, respiratory capacity). Secondary outcome: systolic function (ejection fraction).Findings From initial reference list of 46 selected studies, 22 were extracted presenting the encompassing a total sum of 11,372 subjects that were included in the meta-analysis with a total follow-up time ranging from 2 to 144 months (12 years). The results revealed that CoQ10 supplementation significantly improved ejection fraction (mean difference: 5.6%, 95% CI: 3.2% to 8.0%, p<0.001, I²=25%). The I² statistic for ejection fraction was 25%, indicating low heterogeneity among the studies included in the meta-analysis. Mitochondrial function showed increased ATP production (SMD: 0.82, 95% CI: 0.60 to 1.04, p<0.001, I²=30%) and enhanced respiratory capacity (SMD: 0.75, 95% CI: 0.53 to 0.97, p<0.001, I²=28%). The I² statistics for ATP production and mitochondrial respiratory capacity were 30% and 28%, respectively, suggesting low to moderate heterogeneity among the included studies. Sensitivity analyses confirmed the robustness of the results, with consistent effect sizes and confidence intervals across both fixed-effect and random-effects models, and no significant changes upon excluding high-risk studies. Publication bias was low, as indicated by funnel plots and Egger’s test (p=0.12).Limitations Larger-scale RCTs are needed to confirm findings and determine the optimal dosage and duration of CoQ10 therapy.Conclusion CoQ10 has demonstrated to improve mitochondrial function, systolic performance, and other important cardiovascular health parameters in CVD patients. The evidence here presented strongly supports clinicians in the prescription of CoQ10 supplementation due to its proven efficacy in improving treatment outcomes and mitochondrial function in patients with CVDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors